No internet connection — showing the saved version of the page.

bioAffinity Techn…

USUSD
← to the screener
US:BIAFUS:BIAFW

bioAffinity Technologies, Inc. (US:BIAF) — Biotechnology: Commercial Physical & Biological Resarch. Number of exchanges where the company shares trade: 1. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
bioaffinitytech.com
Investor relations
bioaffinitytech.com/contact/
Sector
Health Care · Biotechnology: Commercial Physical & Biological Resarch
Headquarters
SAN ANTONIO, United States
CEO
Ms. Maria Zannes J.D.
Employees
57
Shares outstanding
8.1 M as of 2026-08-03
Free float
532 257
Market cap
3.69 M USD
Insiders
0.82%
Institutions
5.62%
Industry (SIC)
Services-Commercial Physical & Biological Research
Description

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksBIAFUSD6.055 -1.46%common stock
US USA StocksBIAFWUSD0.5271 +236.59%

Price for 3 months

US:BIAF · USD
up day down day dividend ex-date payment dateHover / tap a day — open, close, high and low prices

Dividends

No dividend payments found (checked 04.10.2026). The company probably does not pay dividends.

advertisement

Company news

Press releases from the company's investor website, updated daily. Links lead to the company's website.

30.09.2026DividendsbioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
22.09.2026bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
17.09.2026bioAffinity Technologies Announces Grant of Hong Kong Patent for Company’s CyPath® Lung Noninvasive Lung Cancer Diagnostic
09.09.2026bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
03.09.2026bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
01.09.2026bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
20.08.2026bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
18.08.2026DividendsbioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
14.08.2026bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
13.08.2026bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
07.08.2026bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
27.07.2026bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
22.07.2026bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
08.07.2026See what’s happening at bioAffinity Technologies…
07.07.2026bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
22.06.2026bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
18.06.2026bioAffinity Technologies Announces Closing of $3.2 Million Offering
17.06.2026bioAffinity Technologies Announces Pricing of $3.2 Million Offering
16.06.2026bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
02.06.2026Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
27.05.2026bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
12.05.2026bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
08.05.2026bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
28.04.2026bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
14.04.2026New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
07.04.2026bioAffinity Technologies’ CyPath® Lung to be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
01.04.2026bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
25.03.2026bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
17.03.2026New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedure
13.03.2026bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

Top holders

HolderStakeSharesReport date
ZANNES MARIA (Chief Exec…≈46.94%280 3592025-01-10
EDWARDS JAMES MICHAEL CP…≈20.11%120 1282025-01-10
ZANNES TIMOTHY PETER (Ge…≈9.17%54 7652025-01-10
REVELES XAVIER TRINIDAD…≈7.02%41 9432025-01-10
Sabby Management, LLC4.06%24 3772026-06-30
Blackrock Inc.1.1%6 5852026-06-30
Vanguard Capital Managem…0.62%3 7032026-06-30
VANGUARD INDEX FUNDS-Van…0.62%3 7032026-06-30
Geode Capital Management…0.57%3 3982026-06-30
J. Safra Sarasin Holding…0.47%2 8402026-06-30
Vanguard Fiduciary Trust…0.34%2 0712026-06-30
Susquehanna Internationa…0.3%1 7912026-06-30
Jane Street Group, LLC0.3%1 7862026-06-30
Fidelity Concord Street…0.28%1 6592026-07-31
State Street Corporation0.27%1 6062026-06-30
HRT Financial LP0.23%1 3892026-06-30
Fidelity Concord Street…0.08%5092026-07-31
Fidelity Concord Street…0.07%4342026-07-31
Fidelity Concord Street…0.03%1672026-07-31
GIRGENTI STEVEN (Officer…—1.09 M2025-01-10

Regulator events

DateRegulatorEventDetails
2026-09-30SECпоточний звітФорма 8-K